论文部分内容阅读
目的坎地沙坦酯与培哚普利联合治疗对高血压患者尿微量白蛋白的影响。方法选择90例原发性高血压合并有微量蛋白尿患者,随机分为坎地沙坦酯组、培哚普利组及坎地沙坦酯与培哚普利联合组,分别予以坎地沙坦酯8mg/d,培哚普利4mg/d,及坎地沙坦酯8mg/d联合培哚普利4mg/d口服,治疗8周,观察治疗前后3组血压及尿微量白蛋白、血肌酐值,并进行比较。结果培哚普利组和坎地沙坦酯组患者经8周治疗,血压降至正常,微量尿蛋白排泄量明显减少(P<0.01),联合组较其他组进一步下降(P<0.05)。培哚普利组有1例出现干咳而改用其他药物。结论坎地沙坦酯与培哚普利联合能更加有效减少高血压患者微量白蛋白尿排泄量,保护肾功能。
Objective To investigate the effect of candesartan cilexetil and perindopril on urine microalbuminuria in patients with essential hypertension. Methods Ninety patients with essential hypertension complicated with microalbuminuria were randomly divided into candesartan cilexetil group, perindopril group, and candesartan cilexetil group and perindopril combined group. The patients were treated with candesartan 8mg / d of tanshinone, 4mg / d of perindopril, 8mg / d of candesartan cilexetil and 4mg / d of perindopril. After 8 weeks of treatment, blood pressure and urine microalbumin, blood Creatinine values, and compared. Results In the perindopril group and the candesartan cilexetil group, the blood pressure dropped to normal after 8 weeks of treatment, and the urinary excretion of urinary protein decreased significantly (P <0.01). The combination group decreased further compared with other groups (P <0.05). One patient in the perindopril group developed a dry cough and switched to another drug. Conclusion The combination of candesartan cilexetil and perindopril can effectively reduce the microalbuminuria excretion and protect renal function in hypertensive patients.